Radical Cystectomy for Bladder Cancer Today—A Homogeneous Series Without Neoadjuvant Therapy

Madersbacher, Stephan; Hochreiter, Werner W.; Burkhard, Fiona C.; Thalmann, George N.; Danuser, Hansjörg; Markwalder, Regula; Studer, Urs E.

doi:10.1200/jco.2003.05.101

Cited by 699 publications

(446 citation statements)

References 20 publications

Supporting

Mentioning

396

Contrasting

Unclassified

Order By: Relevance

“…Madersbacher et al [3] reported long-term outcomes in 507 patients followed for a mean of 45 months after open RC; the 5-year recurrence-free and overall survival were 73% and 62%, respectively, for patients with organ-confined bladder cancer ( ≤ pT2N0), and 56% and 49%, respectively, for patients with extra-organ disease ( > pT2N0). Recent studies identified a survival advantage with an extended lymphadenectomy after open RC [10][11][12].…”

Section: Discussionmentioning

confidence: 99%

“…With documented long-term follow-up data, radical cystectomy (RC) is the standard reference treatment for organ-confined muscle-invasive or high-grade superficial recurrent bladder cancer [1][2][3][4]. Since the first laparoscopic simple cystectomy reported by Parra et al [5] for pyocystis 13 years ago, many institutions worldwide are now using laparoscopic RC (LRC) with various urinary diversions, conducted either intracorporeally or through a mini-laparotomy incision.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Laparoscopic radical cystectomy for cancer: oncological outcomes at up to 5 years

2007

View full text Add to dashboard Cite

OBJECTIVETo report the oncological outcomes at ≤ 5 years after laparoscopic radical cystectomy (LRC), as open RC is the reference standard treatment for muscle-invasive bladder cancer, but interest in LRC is increasing at selected centres worldwide and as yet there are no long-term follow-up data. PATIENTS AND METHODSBetween December 1999 and January 2005, 37 patients (mean age 66 years) had LRC with urinary diversion for invasive bladder cancer; 26 patients (70%) also had an extended pelvic lymphadenectomy. Overall and cancerspecific survival data were obtained from patient charts, radiographic reports, telephone contact, and a check of the Social Security Death Index. RESULTSMost tumours were transitional cell carcinoma (32, 86%), high-grade (grade III in 29, 78%) and high-stage ( ≥ pT2 in 26, 70%). Two patients had a positive surgical margin. The median (range) number of lymph nodes excised was 14 (2-24); seven patients (17%) had node-positive disease (pN1). Follow-up data were available for 35 patients (95%); eight (22%) completed ≥ 5 years of follow-up, and the mean (range) follow-up was 31 (1-66) months. At the last follow-up, 24 patients (65%) were alive with no evidence of disease and 11 (30%) were dead, two (5%) from metastasis and nine (24%) from unrelated causes. The 5-year actuarial overall, cancer-specific and recurrence-free survival was 63%, 92% and 92%, respectively. CONCLUSIONTo our knowledge, this is the first report of ≤ 5-year follow-up after LRC; the data suggest that LRC provides oncological outcomes comparable to contemporary series of open RC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Laparoscopic radical cystectomy for cancer: oncological outcomes at up to 5 years

2007

View full text Add to dashboard Cite

show abstract

“…2 Nevertheless, positive pelvic lymph nodes are generally associated with a poor prognosis and regarded as a poor prognostic parameter in multivariate analysis. [3][4][5] Many investigators underscore the potential curative role of LA in addition to its importance in accurately staging disease. [6][7][8] Even patients with many positive pelvic lymph nodes (pN 2-3) can benefit from LA and achieve a long-term median survival rate of 24% at 10 years with different survival rates for organ-confined tumor stages (ՅpT2) compared to non-organ-confined tumors (ՆpT3).…”

Section: Introductionmentioning

confidence: 99%

The prognostic impact of pelvic lymph node metastasis and lymphovascular invasion on bladder cancer

et al. 2008

View full text Add to dashboard Cite

Objectives: To present long-term results of a single-center series of patients undergoing bilateral pelvic lymphadenectomy and radical cystectomy for bladder cancer and to analyze the impact of pelvic lymph node metastasis and lymphovascular invasion on clinical outcome. Methods: Between 1986 and 2005 833 patients were treated with bilateral pelvic lymphadenectomy and radical cystectomy at our institution. 614 of them with valid clinical follow-up information and no neoadjuvant therapy could be evaluated. Results: Disease-free and overall survival in the entire cohort was 56.7% and 49.5% at 5 years and 52.4% and 38.2% at 10 years, respectively. 28.1% of all patients had pelvic lymph node metastasis. We found organ-confined tumor stages (ՅpT2) in 43.8%. Patients with non-organ-confined tumor stages (ՆpT3) and positive pelvic lymph nodes had a significantly shorter overall survival than those without lymph node metastasis (P < 0.0001). In the subgroup of ՅpT2, the presence of pelvic lymph node metastasis did not show a statistically significant effect on overall survival (P = 0.618). The presence of lymphovascular invasion was associated with an impaired survival (P < 0.0001). In multivariate analysis, pathological tumor stage (P < 0.0001), lymph node stage (ՆpT3) (P = 0.004) and lymphovascular invasion (P = 0.001) were independent prognostic parameters. Conclusions: According to the present series, survival for patients with ՅpT2 does not depend on the lymph node stage. Lymphovascular invasion is an independent parameter of impaired survival and should be determined routinely in cystectomy specimens to identify patients, who may benefit from adjuvant systemic therapy.

show abstract

“…2 The 5-year overall survival rate for early stage bladder cancer is more than 80%, compared with only 20% for advanced stage disease. 3 In patients with lymph node-positive disease, the 5-year overall survival rate is 26%. 4 Although metastatic bladder cancer remains a deadly disease, there are neither efficient therapeutic options for curative treatment, nor sensitive molecular biomarkers for predicting tumor metastasis before they become evident.…”

mentioning

confidence: 99%

Musashi-2 promotes migration and invasion in bladder cancer via activation of the JAK2/STAT3 pathway

Yang

Zhang

Wang

et al. 2016

Laboratory Investigation

View full text Add to dashboard Cite

Musashi-2 (Msi2) is considered to have a crucial role in regulating various key cellular functions. However, the clinical significance and biological role of Msi2 in bladder cancer remains unknown. We examined the expression of Msi2 in bladder cancer cell lines in 167 clinical samples and the biological role of Msi2 in bladder cancer cells. Western blotting was used to investigate the possible mechanism of Msi2-induced migration and invasion in bladder cancer. Msi2 was significantly upregulated in bladder cancer cells and tissues compared with normal bladder urothelial cells and tissues. Immunohistochemical analysis revealed high expression of Msi2 in 57 of 167 (34.1%) bladder cancer specimens. Statistical analysis showed a significant correlation of Msi2 expression with advanced clinical stage, lymph node metastasis, and poor prognosis. Overexpression and ablation of Msi2 promoted and inhibited, respectively, the migration and invasion of bladder cancer cells. Furthermore, we found that Msi2 activated the JAK2/STAT3 pathway and promoted expression of genes downstream of JAK2/STAT3 in bladder cancer. This study demonstrates that Msi2 can induce bladder cancer cell migration and invasion by activating the JAK2/STAT3 pathway, and that Msi2 may be a valuable prognostic biomarker for bladder cancer patients.Laboratory Investigation (2016) 96, 950-958;

show abstract

Radical Cystectomy for Bladder Cancer Today—A Homogeneous Series Without Neoadjuvant Therapy

Cited by 699 publications

References 20 publications

Laparoscopic radical cystectomy for cancer: oncological outcomes at up to 5 years

Laparoscopic radical cystectomy for cancer: oncological outcomes at up to 5 years

The prognostic impact of pelvic lymph node metastasis and lymphovascular invasion on bladder cancer

Musashi-2 promotes migration and invasion in bladder cancer via activation of the JAK2/STAT3 pathway

Contact Info

Product

Resources

About